人体静脉注射甲氨蝶呤后在肝脏和胆汁中的情况。
Methotrexate in liver and bile after intravenous dosage in man.
作者信息
Creaven P J, Hansen H H, Alford D A, Allen L M
出版信息
Br J Cancer. 1973 Dec;28(6):589-91. doi: 10.1038/bjc.1973.190.
Abstract
Measurements of methotrexate have been made in the liver and plasma of 4 patients and in the bile and plasma of 1 patient receiving [(3)H]methotrexate. Projections from a theoretical model of concentration of methotrexate in liver are confirmed but projections of biliary excretion are not.
摘要
已对4例患者的肝脏和血浆以及1例接受[³H]甲氨蝶呤治疗患者的胆汁和血浆进行了甲氨蝶呤测量。肝脏中甲氨蝶呤浓度理论模型的预测得到了证实，但胆汁排泄的预测未得到证实。
相似文献
1
Methotrexate in liver and bile after intravenous dosage in man.人体静脉注射甲氨蝶呤后在肝脏和胆汁中的情况。
Br J Cancer. 1973 Dec;28(6):589-91. doi: 10.1038/bjc.1973.190.
2
Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatography.采用固相萃取和高效液相色谱法对人血清、尿液和胆汁中的甲氨蝶呤及其代谢产物进行快速定量分析。
J Chromatogr. 1989 Feb 24;487(2):476-82. doi: 10.1016/s0378-4347(00)83058-3.
3
Preliminary model for methotrexate pharmacokinetics.甲氨蝶呤药代动力学的初步模型
J Pharm Sci. 1970 Feb;59(2):149-54. doi: 10.1002/jps.2600590203.
4
Some observations on the human pharmacology of methotrexate.关于甲氨蝶呤人体药理学的一些观察
Cancer Treat Rep. 1977 Dec;61(9):1647-56.
5
Methotrexate excretion patterns and renal toxicity after intravenous injection or arterial infusion.静脉注射或动脉灌注后甲氨蝶呤的排泄模式及肾毒性。
Arch Surg. 1969 Mar;98(3):305-8. doi: 10.1001/archsurg.1969.01340090081012.
6
Clearance from plasma and excretion in urine, faeces and bile of an intravenous dose of tritiated vitamin K 1 in man.静脉注射剂量的氚标记维生素K1在人体血浆中的清除率以及在尿液、粪便和胆汁中的排泄情况。
Br J Haematol. 1972 May;22(5):579-88. doi: 10.1111/j.1365-2141.1972.tb05704.x.
7
Inhibition of bilirubin excretion in man during dehydrocholate choleresis.
Gastroenterology. 1973 Dec;65(6):929-35.
8
Plasma concentration, uptake by liver, and biliary excretion of tritiated cardiac glycosides in the isolated perfused guinea-pig liver.离体灌注豚鼠肝脏中氚标记强心苷的血浆浓度、肝脏摄取及胆汁排泄
Br J Pharmacol. 1971 Apr;41(4):648-60. doi: 10.1111/j.1476-5381.1971.tb07073.x.
9
Evaluation of the biliary excretion of pencillin G.青霉素G胆汁排泄的评估。
Chemotherapy. 1979;25(3):129-39. doi: 10.1159/000237832.
10
Concentrations of tritiated methotrexate in ocular compartments, serum and urine after subconjunctival and intravenous injection.结膜下注射和静脉注射后眼内各腔室、血清及尿液中氚标记甲氨蝶呤的浓度。
Can J Ophthalmol. 1980 Oct;15(4):179-82.
引用本文的文献
1
Long-Term Constant Subcutaneous Drug Administration.长期皮下恒速给药。
Methods Mol Biol. 2024;2766:31-36. doi: 10.1007/978-1-0716-3682-4_5.
2
Early clinical indicators of acute kidney injury caused by administering high-dose methotrexate therapy to juvenile pigs.对幼年猪施用高剂量甲氨蝶呤疗法所致急性肾损伤的早期临床指标。
Front Nephrol. 2023 Sep 12;3:1193494. doi: 10.3389/fneph.2023.1193494. eCollection 2023.
3
Overview of Methotrexate Toxicity: A Comprehensive Literature Review.甲氨蝶呤毒性概述：一项全面的文献综述
Cureus. 2022 Sep 23;14(9):e29518. doi: 10.7759/cureus.29518. eCollection 2022 Sep.
4
Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.体外治疗甲氨蝶呤中毒：EXTRIP 工作组的系统评价和建议。
Clin J Am Soc Nephrol. 2022 Apr;17(4):602-622. doi: 10.2215/CJN.08030621. Epub 2022 Mar 2.
5
Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.以D-异构体作为参考标记物估算甲氨蝶呤的肠肝循环。
Eur J Clin Pharmacol. 1984;26(1):103-7. doi: 10.1007/BF00546716.
6
Pharmacokinetics of anticancer drugs in children.儿童抗癌药物的药代动力学
Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002.
7
The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.
Eur J Clin Pharmacol. 1992;42(2):121-5. doi: 10.1007/BF00278469.
8
Clinical pharmacokinetics of methotrexate.甲氨蝶呤的临床药代动力学
Clin Pharmacokinet. 1978 Jan-Feb;3(1):1-13. doi: 10.2165/00003088-197803010-00001.
9
Methotrexate plasma decay kinetics: possible alteration in patients undergoing gut sterilization.甲氨蝶呤血浆衰减动力学：肠道除菌患者中可能的改变。
Br J Cancer. 1976 Nov;34(5):571-5. doi: 10.1038/bjc.1976.213.
本文引用的文献
1
Inhibition of dihydrofolic reductase by aminopterin and amethopterin.氨蝶呤和甲氨蝶呤对二氢叶酸还原酶的抑制作用。
Proc Soc Exp Biol Med. 1958 Feb;97(2):429-31. doi: 10.3181/00379727-97-23764.
2
Methotrexate and folic reductase in human cancer.甲氨蝶呤与人类癌症中的叶酸还原酶
Eur J Cancer (1965). 1966 Jun;2(2):135-42. doi: 10.1016/0014-2964(66)90006-5.
3
Preliminary model for methotrexate pharmacokinetics.甲氨蝶呤药代动力学的初步模型
J Pharm Sci. 1970 Feb;59(2):149-54. doi: 10.1002/jps.2600590203.
4
Methotrexate pharmacokinetics.甲氨蝶呤的药代动力学。
J Pharm Sci. 1971 Aug;60(8):1128-33. doi: 10.1002/jps.2600600803.
5
Transport and binding of methotrexate in vivo.
J Pharm Sci. 1973 Jun;62(6):882-90. doi: 10.1002/jps.2600620603.
6
The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.
Cancer Res. 1965 Aug;25(7):1018-24.
Zotero 插件